News, Resources, and Events Tagged 'Intellectual Property'
A bitter fight in Washington state over whether to label foods with ingredients that have been genetically modified has attracted tens of millions of dollars in spending, more than $27…Read More
ABOUT THE SPEAKER Chris Hansen joined the ACLU in 1973. He spent 10 years at the NYCLU specializing in complex litigation seeking reform of the mental retardation and mental health…Read More
"'M&M chocolate candies are made with a precision far beyond the capabilities of many drug manufacturers.' This is the intriguing opening to a thorough critique of innovation in pharmaceutical manufacturing by Nicholson…Read More
In June 2013, the Supreme Court held that naturally occurring gene sequences and their naturally occurring derivatives are not patent eligible. This link includes a brief summary of the case,…Read More
Shortly after the Supreme Court ruling in Myriad, this article summarizes the implications of the decision and its influence on the biotech industry.Read More
Issues and Case Studies in Clinical Trial Data Sharing:
What Have We Learned?
Objectives: To convene key global stakeholders on a neutral platform to review evidence from recent case studies in clinical trial…Read More
This article addresses misconceptions regarding gene patents and whole-genome sequencing.Read More
In this case, the Supreme Court held that the processes involved in a test for proper dosages of drug treatments are unpatentable laws of nature.Read More
This article discusses the implications of the Mayo v. Prometheus decision, including its potential impact on gene patents. It also suggests possible routes that Congress can take on the issue…Read More
This panel examined current legislative debates concerning the development of regulatory approval processes for follow-on biologics, or large molecule drugs that…Read More